Status: Recruiting
MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure.
A phase II trial of a reduced intensity conditioned (RIC) allogeneic hematopoietic cell transplant (HCT) with post-transplant cyclophosphamide (PTCy) for idiopathic severe aplastic anemia (SAA), paroxysmal nocturnal hemoglobinuria (PNH), acquired pure red cell aplasia (aPRCA), or acquired amegakaryocytic thrombocytopenia (aAT) utilizing population pharmacokinetic (popPK)-guided individual dosing of pre-transplant conditioning and differential dosing of low dose total body irradiation based on age, presence of myelodysplasia and/or clonal hematopoiesis.
Participants needed: 60
Trial details
Phase: Phase 2Age: 0-75Biological sex: AllType: InterventionalSponsor: Masonic Cancer Center, University of MinnesotaUpdated: Jun 3, 2026Locations: 1
Eligibility criteria
Platelets <20,000/uL or transfusion dependent [+10]
Pregnant, breastfeeding or intending to become pregnant during the study. Person... [+8]